Viewing Study NCT04200456


Ignite Creation Date: 2025-12-24 @ 11:28 PM
Ignite Modification Date: 2026-02-25 @ 9:44 PM
Study NCT ID: NCT04200456
Status: TERMINATED
Last Update Posted: 2025-03-18
First Post: 2019-12-13
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Sponsor: UCB Biopharma SRL
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Immune Thrombocytopenia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ITP View
None UCB7665 View
None Rozanolixizumab View
None Primary immune thrombocytopenia View